March 7, 2024 AlzeCure presents new preclinical data with NeuroRestore ACD856 at leading Alzheimer’s conference
March 5, 2024 AlzeCure publishes clinical results supporting continued development of NeuroRestore ACD856 against Alzheimer’s
February 12, 2024 AlzeCure Pharma broadcasts live expert event on Alzheimer’s around highly current gamma-secretase modulators
February 6, 2024 AlzeCure gets Late Breaking abstract of new preclinical data with ACD856 accepted at AD/PD 2024 conference
January 31, 2024 AlzeCure CEO Martin Jönsson to present at the international investor conference BioCapitalEurope
January 29, 2024 AlzeCure selects drug candidate and enters next phase of development with TrkA-NAM ACD137 against severe pain
January 17, 2024 The government draws attention to Swedish Alzheimer’s research and together with the Swedish Alzheimer’s Foundation visit AlzeCure Pharma